ADICET BIO INC's ticker is ACET and the CUSIP is 007002108. A total of 82 filers reported holding ADICET BIO INC in Q4 2021. The put-call ratio across all filers is 0.81 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,091,964 | -43.6% | 797,054 | 0.0% | 0.34% | -35.8% |
| Q2 2023 | $1,936,841 | -57.8% | 797,054 | 0.0% | 0.53% | -61.5% |
| Q1 2023 | $4,591,031 | -18.7% | 797,054 | +26.2% | 1.38% | -13.5% |
| Q4 2022 | $5,646,093 | -57.6% | 631,554 | -32.5% | 1.59% | -55.6% |
| Q3 2022 | $13,307,000 | -2.6% | 935,766 | 0.0% | 3.58% | -3.9% |
| Q2 2022 | $13,662,000 | -4.4% | 935,766 | +30.7% | 3.72% | -0.0% |
| Q1 2022 | $14,296,000 | +11.5% | 715,872 | -2.4% | 3.72% | +15.5% |
| Q4 2021 | $12,823,000 | +334.7% | 733,172 | +94.8% | 3.22% | +311.7% |
| Q3 2021 | $2,950,000 | -23.8% | 376,281 | 0.0% | 0.78% | -3.3% |
| Q2 2021 | $3,872,000 | -23.1% | 376,281 | -2.3% | 0.81% | -32.2% |
| Q1 2021 | $5,037,000 | +362.1% | 385,077 | +396.4% | 1.20% | +268.8% |
| Q4 2020 | $1,090,000 | +35.7% | 77,577 | +14.8% | 0.32% | +24.1% |
| Q3 2020 | $803,000 | – | 67,577 | – | 0.26% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 1,615,385 | $20,968,000 | 7.24% |
| Consonance Capital Management LP | 1,216,860 | $15,917,000 | 1.70% |
| VR Adviser, LLC | 1,000,000 | $13,080,000 | 1.42% |
| Johnson & Johnson Innovation - JJDC, Inc. | 728,944 | $9,535,000 | 1.24% |
| DAFNA Capital Management LLC | 385,077 | $5,037,000 | 1.20% |
| Ally Bridge Group (NY) LLC | 425,000 | $5,559,000 | 1.07% |
| Orbimed Advisors | 7,232,856 | $94,606,000 | 0.88% |
| Avidity Partners Management LP | 2,230,000 | $29,168,000 | 0.81% |
| Altium Capital Management LP | 142,289 | $1,861,000 | 0.52% |
| Nantahala Capital Management | 395,875 | $5,178,000 | 0.15% |